Table 2.
Ongoing trials in basal cell carcinoma (BCC).
| NCT Identifier | Study Title | Conditions | Phases | Patients | |
|---|---|---|---|---|---|
| Topical Treatment | NCT05157763 | A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma | Superficial or nodular BC | PHASE1/2 | 32 |
| NCT00604890 | Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma | Superficial BCC | PHASE1/2 | 186 | |
| NCT03180528 | Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer | BCC | PHASE2 | 30 | |
| HH Inhibitors | NCT02667574 | Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC) | BCC | PHASE2 | 55 |
| NCT04806646 | Tailored Sonidegib Schedule After Complete Response in BCC | laBCC | PHASE2 | 21 | |
| NCT02690948 | Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer | Metastatic or unresectable BCC | PHASE1/2 | 16 | |
| NCT06344052 | To Assess the Safety and Efficacy of SP-002 With Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma | Locally advanced BCC | PHASE2 | 80 | |
| NCT03035188 | Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma | BCC | PHASE2 | 40 | |
| NCT03972748 | Use Of Oral Itraconazole In Patients With Locally Limited Basocellular Carcinoma Of Skin. | BCC | NA | 28 | |
| NCT02735356 | Topical Itraconazole in Treating Patients With Basal Cell Cancer | BCC | EARLY PHASE1 |
9 | |
| NCT02828111 | Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas | Nodular BCC | PHASE2 | 36 | |
| NCT01700049 | Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes | BCC | PHASE2 | 28 | |
| Immunotherapy | NCT01327053 | A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma | Locally advanced or metastatic BCC | PHASE2 | 230 |
| NCT04679480 | Anti-PD1-antibody and Pulsed HHI for Advanced BCC | Advanced BCC | PHASE2 | 20 | |
| NCT03521830 | Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma | Metastatic or unresectable BCC | PHASE2 | 57 | |
| NCT03132636 | PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy | BCC | PHASE2 | 138 |